CTI BioPharma
CTIC
$9.09
Share price
0.00%
Change (1 day)
30.79%
Change (1 year)
Categories
CTI BioPharma (CTIC) - Total debt
Total debt on the balance sheet as of March 2023 : $48.89 M
According to CTI BioPharma 's latest financial reports the company's total debt is $48.89 M. A company’s total debt is the sum of all current and non-current debts.
CTI BioPharma - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $49.95 M | -1.18% |
| 2021-12-31 | $50.55 M | 862.06% |
| 2020-12-31 | $5.25 M | -57.14% |
| 2019-12-31 | $12.26 M | -12.92% |
| 2018-12-31 | $14.07 M | 0.43% |
| 2017-12-31 | $14.01 M | -27.21% |
| 2016-12-31 | $19.26 M | -65.99% |
| 2015-12-31 | $56.63 M | 225.89% |
| 2014-12-31 | $17.37 M | 30.59% |
| 2013-12-31 | $13.3 M | |
| 2012-12-31 | $N/A | |
| 2010-12-31 | $28.23 M | -56.78% |
| 2009-12-31 | $65.31 M | -55.28% |
| 2008-12-31 | $0.14 B | -1.52% |
| 2007-12-31 | $0.14 B | -11.05% |
| 2006-12-31 | $0.16 B | -28.64% |
| 2005-12-31 | $0.23 B | 18.88% |
| 2004-12-31 | $0.19 B | 2.43% |
| 2003-12-31 | $0.19 B | 63.5% |
| 2002-12-31 | $0.11 B | -34.28% |
| 2001-12-31 | $0.17 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $26.34 B | 53,786.90% | 🇨🇭 Switzerland |
 Eli Lilly LLY | $25.22 B | 51,490.76% | 🇺🇸 USA |
 Amgen AMGN | $64.61 B | 132,046.44% | 🇺🇸 USA |
 Baxter BAX | $14.36 B | 29,277.24% | 🇺🇸 USA |
 Incyte INCY | $38.28 M | -21.70% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $41.46 B | 84,702.13% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $20.15 B | 41,116.89% | 🇮🇱 Israel |